ArriVent BioPharma Reports Full Year 2023 Financial Results
Provided By GlobeNewswire
Last update: Mar 28, 2024
NEWTOWN SQUARE, Pa., March 28, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (“Company” or “ArriVent”) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results for the full year ended December 31, 2023, and highlighted recent company progress.
Read more at globenewswire.com
